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Porcine endogenous retrovirus A (PERV A)In vitro screening of randomized FeLV Envelope libraries identiﬁed the CP isolate, which enters cells through
HuPAR-1, one of two human receptors utilized by porcine endogenous retrovirus-A (PERV-A), a distantly re-
lated gammaretrovirus. The CP and PERV-A Envs however, share little amino acid homology. Their receptor
utilization was examined to deﬁne the common receptor usage of these disparate viral Envs. We demonstrate
that the receptor usage of CP extends to HuPAR-2 but not to the porcine receptor PoPAR, the cognate receptor
for PERV-A. Reciprocal interference between virus expressing CP and PERV-A Envs was observed on human
cells. Amino acid residues localized to within the putative second extracellular loop (ECL-2) of PAR-1 and
PAR-2 are found to be critical for CP envelope function. Through a panel of receptor chimeras and point mu-
tations, this area was also found to be responsible for the differential usage of the PoPAR receptor between CP
and PERV-A.
© 2012 Elsevier Inc. All rights reserved.Introduction
Retroviral entry is an intricate process involving coordinated in-
teractions between the retroviral envelope (Env) and a speciﬁc host
receptor. The expression pattern of this receptor therefore is a
major determinant of retroviral tropism. In turn, altering the receptor
utilization retargets the retrovirus to cells or tissues that express the
alternative receptor(s); a feature that can be exploited to create tar-
geted retroviral vectors for gene therapy applications.
By randomizing the receptor-binding domain of feline leukemia
virus (FeLV), novel Envs have been isolated which utilize receptors
outside of the FeLV interference group (Bupp and Roth, 2002; Bupp
and Roth, 2003; Mazari et al., 2009). This method only alters a small
region of the Env and thus does not interfere with its processing or
fusogenic properties. Furthermore, the isolation process screens for
only functional envelopes (Bupp and Roth, 2002) and little to nos Lane Rm 636 Piscataway, NJ
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rights reserved.background is observed on cells that do not express the viral receptor
(Mazari et al., 2009; Sarangi et al., 2007). While this method holds
great promise for creating a collection of functional, retargeted Envs,
examining the receptor usage of those that have been isolated thus
far is vital to ﬁne tuning this system and understanding its full
potential.
CP is one such Env isolate derived through this in-vitro system of
molecular evolution and selection (Mazari et al., 2009). Its host recep-
tor was isolated and determined to be the same receptor utilized by
porcine endogenous retrovirus A (PERV-A) (Ericsson et al., 2003), a
distantly related gammaretrovirus that shares low homology to CP
(32% identity; 46% homology within SU). This receptor, HuPAR-1, ini-
tially reported to function as a G-protein coupled receptor for
gamma-hydroxy butyrate (Andriamampandry et al., 2007), has sub-
sequently been characterized as a riboﬂavin transporter (Yao et al.,
2010). PERV-A is also able to utilize a second human receptor,
HuPAR-2, also reported to function as a riboﬂavin transporter with
86.5% sequence identity to HuPAR-1 (Ericsson et al., 2003; Yonezawa
et al., 2008).
In this report we have further examined the receptor usage of CP
and determined that, similar to PERV-A, CP is able to utilize both of
the human receptors, HuPAR-1 and -2, yet is unable to utilize PERV-
A's constitutive receptor, the porcine homologue, PoPAR. Unlike the
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homologue of PAR that shares similar levels of identity to both
HuPAR-1 and HuPAR-2 (approximately 84% in each case) (Ericsson
et al., 2003). Furthermore, the data demonstrate that, while CP inter-
acts with a similar region on the receptor surface, the interactions be-
tween CP and HuPAR are distinct from those between the receptor
and PERV-A. These ﬁndings validate the method through which CP
was isolated as an efﬁcient means of creating novel and functional
Env-receptor pairs.
Results
CP tropism and interference studies
Previous studies of the laboratory-generated CP Env isolate identi-
ﬁed the GPR172A gene as the host receptor (Mazari et al., 2009). Re-
markably, this protein was previously identiﬁed as one of the
receptors for the PERV-A virus (HuPAR-1). Virus bearing the CP Env
was unable to infect cells of murine origin, a characteristic similar to
PERV-A Env (Takeuchi et al., 1998; Wilson et al., 2000). This common
receptor usage was striking given the lack of homology between the
two Envelopes (Fig. 1). The SU proteins of these two Envs show
only 32% identity and 46% homology. Additionally, within the pro-
posed receptor binding domain VRA (underlined region), show onlyPERV-A    (1) MHPTLSRRHLPIRGGKPKRL
CP    (1) ----------MESPTHPK--
PERV-A   (51) NSHKPLSLTWLLTDSGTGIN
CP   (37) SPHQIYNVTWVITNVQTNTQ
PERV-A (96) P-------GLND--QA----
CP   (87) PRYLCRRTGCSWSSKYGCKT
NNNNNNNNNNN^
PERV-A (128) NPQDFFCKQWSCVTSNDGNW
CP  (137) GAQDGFCAAWGCETTGEAWW
PERV-A  (178) WKDWQQRVQKDVRNKQISCH
CP  (180) --------------------
PERV-A  (228) IVYYGGSGRKKGSVLTIRLR
CP  (205) LRLYR-TGYDPIALFTVSRQ
PERV-A  (275) ---R-PSPNPSDYNTTSGSV
CP  (253) SKVATQRPQTNESAPRSVAP
PERV-A  (321) EATSSCWLCLASGPPYYEGM
CP  (303) NKTKDCWLCLVSRPPYYEGI
PERV-A  (371) GKGTCIGMVPPSHQHLCNHT
CP  (353) GQGLCIGTVPKTHQALCNKT
PERV-A  (421) STLVFNQTKDFCVMVQIVPR
CP  (401) SMAVLNWTSDFCVLIELWPR
PERV-A  (471) VMLG----LGVAAGVGTGTA
CP  (450) LMLGGLTVGGIAAGVGTGTK
PERV-A  (517) VSNLEESLTSLSEVVLQNRR
CP  (495) ISALEKSLTSLSEVVLQNRR
PERV-A  (567) RDSMNKLRERLEKRRREKET
CP  (545) RDNMAKLRERLKQRQQLFDS
PERV-A  (617) LLLTVGPCIINKLIAFIRER
CP  (595) LILLFGPCILNRLVQFVKDR
Fig. 1. Alignment of CP and PERV-A Env sequences. The SU proteins from CP and PERV-A w
FeLV-A VRA (based on homology to FeLV-B) is underlined (Barnett et al., 2003; Rohn et al.,
randomized library is highlighted in bold with an arrow indicating the essential Trp residue
R395 and V433 are highlighted in bold (Argaw et al., 2008).3 homologues within the entire 36aa domain. Additionally, two spe-
ciﬁc residues in the PERV-A C-terminal region of SU (Argaw et al.,
2008) have been shown to inﬂuence human cell tropism. PERV-A
V433 lies in a cluster of conserved residues between PERV-A and CP
(residue 413 in CP) while R395 in PERV-A, critical for infection of
human cells, is a threonine in the corresponding position of CP SU
and is found within a domain of amino acids lacking homology be-
tween the two envelopes (position 377).
To extend our understanding of the receptor usage of CP and
PERV-A, viral titers were measured on a panel of cell lines expressing
the human and porcine receptors (Fig. 2, panels A and B), as well as in
viral interference studies (Fig. 2, panels A and C). Virus bearing the CP
Env was capable of infecting 293HEK cells with titers of 7.3×104 lacZ
staining units (LSU)/ml compared to virus bearing PERV-A, which
produced titers of only 2.2×103 LSU/ml. Additionally, the CP Env
was non-permissive in SIRC cells previously shown to be resistant
to PERV-A infection (Ericsson et al., 2003). Introduction of HuPAR-1
into SIRC cells restored viral titers of virus bearing CP Env to levels
of 6.3×103 LSU/ml, conﬁrming that HuPAR-1 functions as the viral
receptor. In the CP receptor isolation, the HuPAR-2 homologue was
not identiﬁed (Mazari et al., 2009). To analyze the ability of HuPAR-
2 to serve as an alternative CP receptor, HuPAR-2 was introduced
into SIRC cells. Titers of >104 LSU/ml were observed on the SIRC-
HuPAR-2 cells, for both the CP and PERV-A virus (7.1×104 andKIPLSFASIAWFLTLSITPQVNGKRLVDSP
--PSKDKTLSWNLVFLVGILFTIDIGMANP
INSTQGEAPLGTWWPELYVCLRSVI-----
ANATSMLGTLTDVYPTLHVDLCDLVGDTWE
-TPPDVLRAYGFYVCPGPPNNE--E--YCG
TDRKKQQQTYPFYVCPGHAPSLGPKGTHCG
KWPVSQQDRVSYSFVNNPTSYNQFNYGHGR
KP------SSSWDYITVKRGSSQDNNCEG-
SLDLDYLKISFTEKGKQENIQKWVNGMSWG
--KCNPLILQFTQKGKQ---ASWDGPKMWG
IETQMEPPVAIGPNKGLAEQGPPIQEQ---
VST-ITPPQAMGPNLVLPDQKPPSRQSQTG
PTEPNITIKTGAKLFNLIQGAFQALNSTTP
TTVGPKRIGTGDRLINLVQGTYLALNATDP
ARGGKFNVTKEHRDQCTWGSQNKLTLTEVS
AILGNYSNQTNPPPSCLSIPQHKLTISEVS
EAFNRTSESQYLVPGYDRWWACNTGLTPCV
QQGHTG--AHYLAAPNGTYWACNTGLTPCI
VYYYPEKAVLDEYDYRYNRPKREPISLTLA
VTYHQPEYVYTHFAKAVRFR-REPISLTVA
ALITGPQQLEKGLSNLHRIVTEDLQALEKS
ALLETAQ-----FRQLQMAMHTDIQALEES
GLDLLFLKEGGLCVALKEECCFYVDHSGAI
GLDILFLQEGGLCAALKEECCFYADHTGLV
TQGWFEGWFNRSPWLATLLSALTGPLIVLL
QQGWFEGWFNRSPWFTTLISSIMGPLLILL
ISAVQIMVLRQQYQSPSSREAGR-
ISVVQALILTQQYQQIKQYDPDRP
ere aligned using the Vector NTI Alignment Software (Invitrogen). The sequence of the
1994). The 11 amino acid CP speciﬁc sequence within VRA selected from the FeLV A/C
(Bupp and Roth, 2002; Rigby et al., 1992). Additionally, the essential PERV-A residues
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Fig. 2. Interference and receptor usage of CP and PERV-A. (A and B). Viral titer of LacZ staining units/ml (LSU/ml) was determined by the transfer of the lacZ marker via retroviral
vectors carrying CP (Black) or PERV-A (Grey) Envs on cells expressing either HuPAR-1 or HuPAR-2, as well as on permissive cells productively infected with the PERV-A strain 14/220
(Harrison et al., 2004). The ﬁgure represents the average of three (A) or four (B) valueswith error bars representing one Standard Deviation (SD). (C) Viral titer based on luciferase trans-
fer, RLU/ml of viral supernatant of pseudotypedMLVparticles displaying either CP (Black) or PERV-A (Grey) Envs to TELCeB cells or TELCeB cells expressing theCP Env (TEL-CP). Theﬁgure
represents the average of 3 experiments with error bars representing 1 SD.
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able to utilize this closely related receptor. Lastly, virus bearing the CP
Env produced no titer on the ST-Iowa porcine cells, which are highly
permissive to PERV-A infection with a titer of PERV-A of 3.1×104
LSU/ml. However, expression of HuPAR-2 in ST-IOWA cells was sufﬁ-
cient to allow for high titer infection (2.8×105 LSU/ml) by virus bear-
ing the CP env (Fig. 2B) demonstrating that there is no post-entry
block in porcine cells but rather that CP is unable to utilize the porcine
receptor, PoPAR.
Viruses are capable of blocking infection of a challenge virus when
both utilize the same host cell-surface receptor protein, a phenome-
non termed receptor interference (Steck and Rubin, 1966). PERV-A
virus was therefore introduced into both permissive human 293
HEK cells, and the SIRC-HuPAR-2 cells, and challenged with virus
bearing CP Env. In the presence of PERV-A, neither CP nor PERV-A
was able to infect either the 293/PERV-A or the SIRC-HuPAR-2/
PERV-A cells (Fig. 2A). Additionally, viral titers were measured on
cells expressing high levels of the CP Env (TEL-CP) as well as on theparental cell line (TEL) which express no viral Env (Fig. 2C). In this
study, ﬁreﬂy luciferase was used as the reporter gene, as these cell
lines already express lacZ. On the parental TEL cell line, CP and
PERV-A had titers of 6.4×103 and 2.2×103 RLU/ml respectively. Ti-
ters were reduced by greater than 100-fold on the CP Env expressing
cell line, TEL-CP, yielding CP and PERV-A viral titers of 33 and 12 rel-
ative luciferase units (RLU)/ml, respectively. The reciprocal interfer-
ence between these two Envs conﬁrms their common receptor usage.
HuPAR/MuPAR chimeras and HuPAR-2 mutants
Previous studies have shown that PERV-A is unable to utilize the
murine receptor homologue, MuPAR (Ericsson et al., 2003;
Mattiuzzo et al., 2007). Through a series of HuPAR-2/MuPAR chimeras
and HuPAR-2 mutants expressed in non-permissive SIRC or QT6 cell
lines, the block in PERV-A receptor function was localized to a single
residue, P109 (Marcucci et al., 2009; Mattiuzzo et al., 2007), which
maps to the interface between the second extracellular loop (ECL)
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HuPAR-2/MuPAR chimeras and HuPAR-2 mutants was used to survey
receptor recognition of CP, shown to utilize HuPAR-2 (Fig. 2A) but in-
capable of infecting cells of murine origin (Mazari et al., 2009). These
data are summarized in Fig. 3A, with the locations of these murine in-
sertions within the HuPAR-2 backbone shown schematically in
Fig. 3B. Titers on the permissive cell line 293HEK were 3.9×104
LSU/ml. For ten point mutants (H110Y, Q108K, H100N, P97S, Q82R,
P73R, V64L, V54L, D40E, and T4P) as well as a triple mutant
(VSV(86,88-89)GGI) and an exchange of the entire third ECL (ECL3),
the titers were similar to that measured on 293HEK (>104 LSU/ml).
No titer however was detected on cells expressing the L109P mutant,
mirroring published data regarding PERV-A titers on cells expressing
the same panel of mutant and chimeric receptors (Mattiuzzo et al.,
2007).
As antibodies capable of reliably distinguishing between HuPAR-1
and HuPAR-2, or between PARs of different mammalian species have
not yet been developed, a surrogate marker was needed to assure
proper expression of the non-functional receptor. In these studies,
all of the constructs were tagged at the C-terminus with eGFP. Similar
levels of ﬂuorescence were measured on cells expressing PAR 2-
L109P-eGFP construct as compared to the functional huPAR-2-eGFP
construct (Fig. 3C), eliminating concerns of misfolding or rapid turn-
over of the non-functional mutant. This data highlights the impor-
tance of the structure of the second extracellular loop in infection
by virus bearing either the CP or PERV-A Envs.
HuPAR/PoPAR chimeras
The most signiﬁcant evidence for differential receptor usage be-
tween CP and PERV-A is found in the inability of CP virus to infect
porcine cells, presumably due to a polymorphism in PERV-A's native
receptor, PoPAR (Fig. 2A). To better understand this, CP titers were
measured on cells expressing HuPAR/PoPAR chimeras in eitherFig. 3. HuPAR/MuPAR chimeras and HuPAR-2 mutants. (A) Viral titer (LSU/ml) was measur
SIRC cells expressing a panel of HuPAR-2/MuPAR chimeras. The ﬁgure shows the average of
of the position of the mutated residue(s) within the chimera. Individual point mutations are
expression in SIRC cells and SIRC cells expressing either HuPAR-2 or the HuPAR-2/L109P mu
solid black line, SIRC cells expressing PAR 2-L109P-eGFP; Dotted grey line, SIRC cells expreHuPAR-1 or HuPAR-2 backbones (Fig. 4). The initial construct trans-
ferred amino acids 64–235 of PoPAR into HuPAR-2. This region encodes
the second and third extracellular loops of PoPAR and contains 49% of
the total mismatches between HuPAR-2 and PoPAR and 63% of themis-
matches localized within the predicted extracellular loops. This PoPAR
insert was further divided into two smaller regions, incorporating resi-
dues 62–169 and 169–235 of PoPAR into HuPAR-2.
CP titers on UMR-106 cells transduced with full-length HuPAR-2
were 4.7×104 LSU/ml. On cells transduced with HuPAR-2/PoPAR64-
169 or HuPAR-2/PoPAR64-235 constructs, no titer was observed. In
contrast, expression of HuPAR2/PoPAR169-235 (containing ECL 3
alone) resulted in viral titers (3.7×104 LSU/ml) comparable to that
of wild-type HuPAR-2. Together, these data place the CP binding
site (the site which determines the differential receptor usage of CP
and PERV-A) to within aa 64–169. The only predicted extracellular
domain within this span is ECL 2.
To further conﬁrm that the region most critical for receptor binding
localized within the second ECL, PoPAR 64–169 was exchanged within
the HuPAR1 backbone aswell. Similarly, while titers on cells expressing
HuPAR-1 were 1.1×105 LSU/ml, no titer wasmeasured on cells expres-
sing the HuPAR-1/PoPAR64-169. Studies indicate HuPAR1 and HuPAR2
maintain similar topology (Supplemental Fig. S1).
Additionally, binding of virus bearing CP could not be detected on
cells expressing the non-functional receptors (data not shown). All
three constructs that were unable to mediate CP binding and entry
(HuPAR-1/PoPAR64-169, HuPAR-2/PoPAR64-169 and 64–235), con-
tained the second ECL of PoPAR. These data coupled with the data
obtained from the MuPAR chimeras demonstrate the critical role
that ECL-2 plays in CP binding to the PERV-A receptors.
HuPAR ﬁne mapping studies
To localize the speciﬁc residues within ECL-2 that are critical for
CP binding and infectivity, CP titers were measured on cellsed by the transfer of the lacZ marker via virus bearing the CP Env into non-permissive
three experiments with error bars representing one SD. (B) A schematic representation
shown by position. Exchange of the entire ECL3 is shown with a thick black line. (C) GFP
tant both of which contained a C-terminal eGFP tag. Solid grey ﬁlled, SIRC control cells;
ssing huPAR-2-eGFP.
UMR-106
HuPAR-2
HuPAR-2/64-169
HuPAR-2/169-235
HuPAR-2/64-235
HuPAR-1
HuPAR-1/64-169
1.E+00              1.E+01               1.E+02               1.E+03               1.E+04               1.E+05              1.E+06
Titer (LSU/ml)
Fig. 4. HuPAR/PoPAR Chimeras. The transfer of the lacZ marker by virus bearing the CP Env was measured on non-permissive UMR-106 cells expressing HuPAR-1/PoPAR and
HuPAR-2/PoPAR chimeras. The chimeric regions are depicted schematically along the Y-axis with the corresponding HuPAR-2 (white), HuPAR-1 (grey) and PoPAR (black) regions
represented accordingly. The ﬁgure represents an average of three experiments with error bars representing one SD.
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second extracellular loop were mutated alone and in combination.
For reference the HuPAR sequence is represented diagrammatically
in Fig. 5C with an alignment of the human and porcine ECL's in
Fig. 5D. For HuPAR-1, a series of six point mutations and one ex-
change of PoPAR residues 102–105 were analyzed. For huPAR-2,
two point mutations (H100Q, L109V) and exchange of residues
VAPV102-105LTVM were generated. In addition, exchange of the en-
tire second extracellular loop (100–109) was generated in both
HuPar-1 and HuPAR-2 backbones. Titers on cells expressing wild-type
HuPAR-1 and −2 were 1.1×105 and 1.2×105 LSU/ml respectively.
The majority of mutations in HuPAR-1 had little effect on CP titers,
with measurements all within 1 order of magnitude of wild-type
HuPAR-1 (Fig. 5A). A similar patternwas seen on theHuPAR-2mutants;
however, a greater than 10-fold decrease in titer was seen on the
HuPAR-2/L109V mutant (Fig. 5B). For both HuPAR-1 and −2, titers
>5×103 LSU/ml were maintained until the entire second ECL was
replaced with that of PoPAR (mutants HuPAR-1/100-109 (Fig. 6A)
and huPAR-2/100-109 (Fig. 5B)). The requirement for such a large
change in sequence in order to prevent receptor usage suggests
that no single residue is required for recognition by CP but rather
virus binding and infection is determined by the overall structure
of the second ECL.
Conﬁrmation of chimera expression
In order to assure that the chimeras that CP was unable to utilize
were properly synthesized and expressed, PERV-A titers were tested
on receptors that were non-permissive to CP (Fig. 6). For the
HuPAR2/PoPAR64-235, 64–169, and 100–109 chimeras, PERV-A pro-
duced titers of 3.6×103, 4.8×103, and 1.1×104 LSU/ml respectively.
These titers were similar to titers measured on cells expressing
wild-type HuPAR-2, 8.2×103 LSU/ml. Similarly, PERV-A produced ti-
ters of 1.3×104 and 7.0×103 LSU/ml on cells expressing the
HuPAR-1 chimeras HuPAR-1/PoPAR 64–235, and 100–109, which
were comparable to PERV-A titers on cells expressing wild-type
HuPAR-1 (3.8×103 LSU/ml). These titers conﬁrm that the receptorswere properly expressed and remained functional. Therefore, the
lack of CP titers and binding was a result of the chimera itself and
not a defect in expression.
Discussion
In this report we have probed the receptor usage of two distantly
related gamma retroviruses, PERV-A and CP, which utilize the same
human receptors. PERV-A evolved naturally to utilize the porcine re-
ceptor PoPAR and fortuitously utilizes the human homologues as
well. CP on the other hand, was selected through in-vitro passage
and screening of a library of Env constructs on human cell lines.
Whereas natural viral evolution is dependent on the presence of
other endogenous and exogenous viruses as well as the host immune
system, the library screening relies only on functional entry. Other
Envs have been developed through the same method as CP which uti-
lize receptors outside of the FeLV interference group (Bupp and Roth,
2003; Bupp et al., 2005). CP is the ﬁrst however, whose receptor was
identiﬁed and found to be related to that utilized by a distantly related
retrovirus. It was of great interest to compare and contrast the receptor
requirements selected by these two independent viruses especially
given their striking lack of homology (32% identity and 46% homology)
(Fig. 1).
For FeLV-A Env, and thus CP, the major determinant for receptor
binding is within the single variable region 1 (VRA) region (Rigby et
al., 1992). This region, (residues 82–117 of the CP sequence) shows
only 3 homologous residues with PERV-A in the entire 36 aa domain.
In contrast, multiple regions of the PERV-A Env are necessary for re-
ceptor binding, entry and human cell tropism (Argaw et al., 2008;
Gemeniano et al., 2006; Harrison et al., 2004). The ability of PERV-A
to recognize PoPAR may therefore be modulated by additional do-
mains of SU that interact with receptor in a way that is unaffected
by the structural differences between the human and porcine
homologues.
Of interest is the observation that both CP and PERV-A demon-
strated ten-fold higher titers on SIRC cells expressing HuPAR-2 than
on SIRC-HuPAR-1. This observation has been extensively studied in
Fig. 5. HuPAR/PoPAR ECL2 mutants. (A and B) The transfer of the lacZ marker by virus bearing the CP Env was measured on non-permissive UMR-106 cells expressing a panel of
HuPAR-1 (Panel A) or HuPAR-2 (Panel B) mutants in which small domains or single residues of the human sequence had been replaced with the corresponding residue from the
PoPAR sequence. The ﬁgure represents the average of three experiments with error bars representing one SD. (C) A schematic representation of ECL2 and the location of the mu-
tations in the constructs used in panels A and B. (D) ECL2 sequence alignment from HuPAR-1, HuPAR-2, and PoPAR (residues 100–109). Residues that are identical in all three re-
ceptors are highlighted.
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-2 have been identiﬁed as riboﬂavin transporters (Yao et al., 2010;
Yonezawa et al., 2008). However, their expression proﬁle and pre-
dicted intracellular domains vary greatly. Interestingly, for PERV-A,
chimera studies between HuPAR-1 and HuPAR-2 expressed in SIRC
cells indicate the region spanning amino acids 152–285 is responsible
for the increase in HuPAR-2 function (Marcucci et al., 2009). This
maps outside the major receptor-binding domain (extracellular loop
2), but includes the large third intracellular loop where the most var-
iation between the two proteins map. Thus, receptor properties be-
yond binding provide advantages for productive infection and high
titer. This difference in titer is not seen when the receptors are
expressed in UMR-106 cells (Fig. 5). Virus bearing CP binds UMR-
106 cells expressing HuPAR-1 and HuPAR-2 at similar levels(Supplemental Fig. S2). This suggests a cell-speciﬁc contribution to
the relative efﬁciency with which these two receptors may be used
for viral entry.
Data obtained bymeasuring titers of virus bearing CP on HuPAR-2/
MuPAR and HuPAR/PoPAR chimeras demonstrates that like PERV-A,
the speciﬁc residues located in ECL-2 region are critical for CP binding
and infection. This region is identical between HuPAR-1 and −2. In
contrast, identity between HuPAR and PoPAR extends to only four
of the ten amino acids within this extracellular loop (Fig. 5D). ECL-2
contains primarily hydrophobic residues (Fig. 5C) and may form a hy-
drophobic pocket on the receptor surface. In a previous study, a tryp-
tophan in the receptor binding region of CP was found to be
absolutely necessary for infection, and even conservative mutations
rendered the virus non-infectious (Mazari et al., 2009). Perhaps the
Fig. 6. Conﬁrmation of functional chimeric receptors utilizing PERV-A infection. Viral titer (LSU/ml) was determined by the transfer of the lacZ reporter gene via retroviral vectors
expressing the CP (Black) or PERV-A (Gray) Env into non-permissive UMR-106 cells and UMR cells expressing the HuPAR/PoPAR chimeras. The ﬁgure represents the average of
three independent experiments with error bars representing 1 SD.
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inverse manner to that seen in HIV, in which a single phenylalanine
residue on the surface of CD4 interacts with a hydrophobic pocket
on the surface of the HIV Env (Kwong et al., 1998). This model is fur-
ther supported by the ability of CP to utilize the HuPAR/PoPAR point
mutants. The majority of the mutations in these chimeras were con-
servative, replacing one non-polar residue with another (V102L,
P104V, V105M, and L109V). These mutants would not be likely to dis-
tort this binding pocket sufﬁciently to prevent the binding of CP.
However, when the entire ECL2 is replaced with that of PoPAR, the
overall conformation of this hydrophobic pocket may be distorted
such that it is no longer accessible to the tryptophan of CP. Deﬁnitive
proof of this model would be greatly assisted by structural informa-
tion of both the FeLV A or CP SU and the HuPAR 1 or 2 receptors.
It is interesting that the same HuPAR/MuPAR mutation (L109P)
modulates infection by both CP and PERV-A. In rhesus monkeys,
cynomolgus macaques and baboons position 109 is a serine and has
been also identiﬁed as critical for PERV-A viral infection. Substitution
of L109S into HuPAR-1 results in loss of PERV-A infection, whereas
conversely substituting S109 to L in rhPAR-1 restores PERV-A infec-
tion (Mattiuzzo and Takeuchi, 2010). Position 109 is predicted to lie
at the junction of the putative second ECL and the fourth transmem-
brane domain of the human receptor (Supplemental Fig. S1). The sub-
stitution of a proline at position 109 may shift this junction, thus
altering both the CP and PERV-A binding epitopes. This is supported
by the Kyte–Doolittle plot, which predicts the second ECL of MuPAR
to be one residue larger and the fourth transmembrane domain to
begin after P109. Interestingly, a serine in this position is predicted
to have the same effect, positioning residue 109 within the 2nd extra-
cellular domain. This offers a unifying explanation for the critical nature
of this position,where PAR receptors non-permissive for CP and PERV-A
infection are predicted to encode a 10 amino acid 2nd extracellular loop.
CP was the second Env from our library of mutated envelopes to
have its receptor identiﬁed. The A5 Env isolate also utilized a multi-
pass transmembrane protein, SLC35F2 (Sarangi et al., 2007), as do
the majority of retroviruses. This common evolutionary outcome
points to multipass transmembrane proteins as being particularly ef-
ﬁcient at providing the features necessary to permit fusion and entry
for gammaretroviruses. It is of interest that there are other examples
of gammaretroviruses from divergent species that utilize identical
multipass transmembrane transporters proteins as their receptors,
for example FeLV-B and GaLV Env use Pit1 (Kavanaugh et al., 1994;Olah et al., 1994; Takeuchi et al., 1992). The close proximity of the re-
ceptor extracellular domains with the host membrane may provide a
spatial advantage for insertion of the viral fusion peptide into the tar-
get membrane. Alternatively, the use of a transporter for viral entry
may allow viral trafﬁcking to a non-degradative pathway than other
cell surface molecules, averting lysosomal degradation (Zhao et al.,
1999). Retroviral retargeting is therefore restricted not only by the
ability to target the virus to a new cell surface protein (Cosset et al.,
1995b; Zhao et al., 1999), but also by the ability to select a target
that will be able to function as a retroviral receptor, and allow appro-
priate intracellular trafﬁcking. The observation that both the natural
selection process (PERV-A) and an in vitro-driven evolutionary pro-
cess (CP) resulted in convergent use of the same receptor, in spite
of primary amino acid sequence divergences as demonstrated here,
suggest that this is not a result of CP mimicking a distantly related
gammaretrovirus, but instead, it is a distinct interaction with two par-
ticularly efﬁcient receptors. This validates the method through which
CP was isolated as a means of creating truly retargeted Env proteins
with novel receptor interaction.
Conclusion
This study illustrates that receptor binding sequences functionally
selected in a screen of an in-vitro derived retroviral Env, resulted in
convergence of receptor use with a naturally occurring retrovirus.
This similar evolutionary endpoint is not a matter of simple molecular
mimicry as evidenced by the lack of primary amino acid homology
between CP and PERV-A and their differential usage of the porcine re-
ceptor. Gammaretrovirus receptor proteins cluster as multipass
transmembrane surface proteins. For viruses encoding the CP and
PERV-A Envs, their common receptor usage extends not only to the
same human receptors but also to a similar extracellular domain.
The evolutionary selection for receptor proteins with similar proper-
ties highlights the importance of receptor contributions towards me-
diating efﬁcient viral entry.
Materials and methods
Cell lines
All media was supplemented with 10% FBS and a 10 μl/ml of
antibiotic-antimycotic mixture (Gibco). The human renal cell
125P.M. Mazari et al. / Virology 427 (2012) 118–126carcinoma cell lines Caki-1 and -2 were maintained in McCoy's 5A
Media; UMR-106 (rat epithelial), 293HEK, and TE671 (human), in
DMEM; and SIRC (lapine) and 143B (human), in minimal essential
media supplemented with 2 mM L-glutamine. SIRC HuPAR-1 and -2
were maintained in minimal essential media supplemented with
2 mM L-glutamine and 400 μg/ml G418. 293 T were maintained in
DMEM supplemented with 400 μg/ml G418. The stable viral producer
cell line TELCeB (Cosset et al., 1995a), expressing Gag-Pol plus pack-
aging the lacZ, gene was maintained in DMEM supplemented with
10 μg/ml BlasticidinS (Invivogen). TELCeB cells stably expressing the
CP Env, TEL-CP (Mazari et al., 2009), as well as 293TCeB cells (Bupp
and Roth, 2002) were maintained in DMEM supplemented with
10 μg/ml BlasticidinS and 400 μg/ml G418. UMR-106 expressing the
His-tagged receptors and chimeras in pBABE-puro were created by
transfecting 5×106 293TCeB cells with 5 μg of pHIT-G (Fouchier et
al., 1997) (encoding the vesicular stomatitis virus G protein) and
5 μg of plasmid encoding the receptor. Viral supernatant was collect-
ed after 48 h and used to infect approximately 5×105 UMR-106 cells.
The cells were placed into selection with 2 μg/ml puromycin after
48 h. ST-IOWA cells (porcine) were cultured in DMEM supplemented
with 10% FBS and 1% Penicillin and Streptomycin, 1% L-glutamine and
1% sodium pyruvate. Sirc Hu/MuPAR cells are lapine cells that stably
express chimeric human, HuPAR-2/MuPAR receptors. These cell
lines were prepared and maintained as previously described
(Marcucci et al., 2009).
Hemagglutinin tagged receptors
Hemagglutinin tags were added to the N or C terminus of the
HuPAR-1 cDNA via PCR with KOD Hot Start Polymerase (Novagen).
5′ ATP overhangs were added to the PCR product by incubating
10 μl of the puriﬁed PCR product with 10 μl of Taq Master Mix
(USB) at 70 °C for 30 min. The products were then Topo-TA cloned
into pCRII (Invitrogen). An EcoRI fragment, encoding the tagged
HuPAR insert was excised from the pCRII-HA-Par1 and Par1-HA plas-
mids and exchanged into pcDNA3.1/Zeo(+). 10 μg of the plasmid
DNA, isolated using the Endofree Plasmid Puriﬁcation Kit (Qiagen)
was transfected into 293 T cells via Lipofectamine 2000 (Invitrogen).
Receptor expression in cells was analyzed 48 h after transfection.
Flow cytometry
All steps were performed in PBS with 5% FBS. Approximately 106
cells were harvested with PBS containing 5 mM EDTA, washed with
2 ml wash buffer and incubated on ice for 1 h with the rabbit poly-
clonal anti-HA antibody HA.11 (Covance) at a 1:100 dilution. The
cells were washed and incubated on ice for 45 min with an FITC con-
jugated polyclonal goat anti-rabbit IgG (Sigma) at a 1:100 dilution.
After an additional wash, ﬂuorescence was measured on a Beckman
Coulter Cytomics FC500 at the Cytometry Core Facility at the Environ-
mental and Occupational Health Sciences Institute of the University of
Medicine and Dentistry of New Jersey.
Binding assay
Virus bearing the CP Env was harvested from a conﬂuent plate of
TEL-CP cells and 4 ml was applied to approximately 106 UMR-106
cells expressing either HuPAR-1 or HuPAR-2 on ice for 45 min. Virus
bound to the cell surface was measured as previously described
(Kadan et al., 1992).
Viral Titers
Approximately 106 TEL-CP cells were plated into a 10 cm2 plate
containing 10 ml of media in the absence of Blasticidin S or G418.
Viral supernatant was collected 48 h later, ﬁltered through 0.45 μmﬁlters, brought to a ﬁnal concentration of 8 μg/ml polybrene, and ap-
plied to cells. After 3 h, the viral supernatant was removed, the cells
were washed with PBS, and fresh media was applied. After 72 h titers
were measured as previously described (16). For infectivity assays
with PERV-A, 293 cells productively infected with the PERV-A isolate
14/220, kindly provided by Clive Patience, were transduced with
VSV-G pseudotyped MLV vectors carrying the RT43.2TnIsbgal plas-
mid, a murine leukemia virus-based vector genome containing the
packaging signal and the β-galactosidase gene (Ting et al., 1998) to
generate PERV-A 14/220 LacZ (hereafter referred to as PERV-A). Super-
natants were collected from conﬂuent monolayers of 293/PERV-A 14/
220 LacZ producer cells, ﬁltered through 0.45 mM ﬁlter, adjusted to
8 μg/ml polybrene and added to target cells, as described above. Detec-
tion of infected cells was performed by histochemical staining and mi-
croscopic enumeration of beta-galactosidase-positive cells, as described
previously (Wilson and Eiden, 1991).
For measurement of PERV-A titers on the HuPAR/PoPAR chimeras,
approximately 3.5×105 TELCeB cells (Cosset et al., 1995a) were plat-
ed in 10 cm dishes. The next day the cells were transfected with 7 μg
of pClneoPERV-Aenv1.38.2CW expressing the PERV-A Env (Takeuchi
et al., 1998; Wilson et al., 2000) using the Lipofectamine 2000 kit
according to the manufacturers protocol. The next day the cells
were induced with 10 mM sodium butyrate for 6 h. 48 hours later
virus was harvested and used to infect the target cell lines as above.
Luciferase based viral interference assay
A bicistronic MMLV-based vector designated pCPILW was gener-
ated, with CP expression driven by the LTR and luciferase gene driven
by an IRES (X. Zhang, personal communication). A derivative viral
construct lacking the Env gene cassette was used as negative control
(pdEnvILW). PERV-A-pseudotyped retroviral particles were produced
by the cotransfection of PERV-A vector (pCIneoPERV-Aenv1.38.2CW)
and RR460 vector (gift of Dr. Allen Rein (NIH), expressing the lucifer-
ase gene from the MuLV LTR). The positive control cotransfected
pHIT-G (Fouchier et al., 1997) expressing VSV-G with the Env- vector.
293TCeB cells were transfected either with pCPILW (10 μg) vector,
PERV-A (10 μg) plus RR460 vector (5 μg), pdEnvILW (10 μg) or VSV-
G (5 μg) plus pdEnvILW vector (10 μg), using the Lipofetamine 2000
transfection kit (Invitrogen), as recommended by the manufacturer.
One day after transfection, cells were incubated with 10 mM of sodi-
um butyrate at 37 °C for 6 h. Viral supernatant was collected 48 h
post-transfection and ﬁltered through a 0.45 μM ﬁlter. 2×105 viral
targeting cells, TELCeB and TELCeB/CP, were infected with each viral
supernatant in either 1 ml or 4 ml. Each transduction was repeated
in triplicate. The cells were incubated with viral particles overnight
followed by luciferase assay 48-h post-transduction.
For the luciferase assay, transduced cells were collected and lysed
in 150 μl cell lysis buffer using the Luciferase Assay System Kit (Pro-
mega). Cell lysate (5, 10 and 20 μl) were then added to 100 μl sub-
strate buffer and measured immediately with a GloMax 20/20
luminometer programmed to perform a 2-second measurement
delay followed by a 10 second measurement of luciferase activity.
The ﬁnal reading was adjusted as relative luciferase units (RLU) per
μl cell lysate per ml viral supernatant (RLU//ml).
HuPAR/MuPAR mutants
HuPAR-2 mutants containing MuPAR substitutions were created
and expressed in the non-permissive cell line SIRC as previously de-
scribed (Marcucci et al., 2009).
HuPAR/PoPAR chimeras
HuPAR-1 and -2 constructs with N-terminal His6 tags were gener-
ated via PCR with KOD polymerase and inserted into pGEM-T
126 P.M. Mazari et al. / Virology 427 (2012) 118–126(Promega). The PoPAR cDNA from positions 192 to 706 (aa 64–235)
fused in frame with a BamHI restriction site at the 3’ end was synthe-
sized (GeneScript) and used as a template. The BstEII–XhoI, XhoI–
BamHI, and BstEII–BamHI fragments, encoding amino acids 64–169,
169–235, and 64–235 respectively, were exchanged into His-
HuPAR-2-pGEM-T. The full-length chimera was then exchanged into
pBABE-puro (Addgene). The BstEII–Xho fragment was also ex-
changed into HuPAR-1 in the same fashion.
HuPAR-1 and -2 mutants were created via overlapping PCR with
KOD polymerase. The ﬁnal product was gel isolated and puriﬁed,
digested with EcoRI and BamHI for HuPAR-1 or EcoRI and SalI for
HuPAR-2 and inserted into pBABE-puro. All mutations were veriﬁed
by sequencing.
Acknowledgments
This is work is supported by NIH grant RO1 CA49932 to MJR. PM
was supported by fellowship 707060 from the NJCCR and T32
GM008360 from the NIH. The contributions by DRS were supported
by NIH grant R01 AI052349.
Appendix A. Supplementary data
Supplementary data to this article can be found online at doi:10.
1016/j.virol.2012.02.012.
References
Andriamampandry, C., Taleb, O., Kemmel, V., Humbert, J.P.L., Aunis, D., Maitre, M., 2007.
Cloning and functional characterization of a gamma-hydroxybutyrate receptor
identiﬁed in the human brain. FASEB J. 21 (3), 885–895.
Argaw, T., Figueroa, M., Salomon, D.R., Wilson, C.A., 2008. Identiﬁcation of residues out-
side of the receptor binding domain that inﬂuence infectivity and tropism of por-
cine endogenous retrovirus. J. Virol. 82 (15), 7483–7491.
Barnett, A.L., Wense, D.L., Li, W., Fass, D., Cunningham, J.M., 2003. Structure and mech-
anism of a coreceptor for infection by a pathogenic feline retrovirus. J. Virol. 77 (4),
2717–2729.
Bupp, K., Roth, M.J., 2002. Altering retroviral tropism using a random display Envelope
library. Mol. Ther. 5, 329–335.
Bupp, K., Roth, M.J., 2003. Targeting a retroviral vector in the absence of a known cell-
targeting ligand. Hum. Gene Ther. 14, 1557–1564.
Bupp, K., Sarangi, A., Roth, M.J., 2005. Probing sequence variation in the receptor-
targeting domain of feline leukemia virus envelope proteins with peptide display
libraries. J. Virol. 79 (3), 1463–1469.
Cosset, F., Takeuchi, Y., Battini, J., Weiss, R., Collins, M., 1995a. High-titer packaging cells pro-
ducing recombinant retroviruses resistant to human serum. J. Virol. 69 (12), 7430–7436.
Cosset, F.-L., Morling, F.J., Takeuchi, Y., Weiss, R.A., Collins, M.K.L., Russell, S.J., 1995b.
Retroviral retargeting by envelopes expressing an N-terminal binding domain. J.
Virol. 69, 6314–6322.
Ericsson, T.A., Takeuchi, Y., Templin, C., Quinn, G., Farhadian, S.F., Wood, J.C., Oldmixon,
B.A., Suling, K.M., Ishii, J.K., Kitagawa, Y., Miyazawa, T., Salomon, D.R., Weiss, R.A.,
Patience, C., 2003. Identiﬁcation of receptors for pig endogenous retrovirus. PNAS
100 (11), 6759–6764.
Fouchier, R.A.M., Meyer, B.E., Simon, J.H.M., Fischer, U., Malim, M.H., 1997. HIV-1 infec-
tion of non-dividing cells: evidence that the amino-terminal basic region of the
viral matrix protein is important for Gag processing but not for post-entry nuclear
import. EMBO J. 16, 4531–4539.Gemeniano, M., Mpanju, O., Salomon, D.R., Eiden, M.V., Wilson, C.A., 2006. The infectiv-
ity and host range of the ecotropic porcine endogenous retrovirus, PERV-C, is mod-
ulated by residues in the C-terminal region of its surface evelope protein. Virology
346 (1), 108–117.
Harrison, I., Takeuchi, Y., Bartosch, B., Stoye, J.P., 2004. Determinants of high titer in re-
combinant porcine endogenous retroviruses. J. Virol. 78 (24), 13871–13879.
Kadan, M.J., Sturm, S., Anderson, W.F., Eglitis, M.A., 1992. Detection of receptor-speciﬁc
murine leukemia virus binding to cells by immunoﬂuorescence analysis. J. Virol. 66
(4), 2281–2287.
Kavanaugh, M.P., Miller, D.G., Zhang, W., Law, W., Kozak, S.L., Kabat, D., Miller, A.D.,
1994. Cell-surface receptors for gibbon ape leukemia virus and amphotropic mu-
rine retrovirus are inducible sodium-dependent phosphate symporters. Proc.
Natl. Acad. Sci. U. S. A. 91 (15), 7071–7075.
Kwong, P.D., Wyatt, R., Robinson, J., Sweet, R.W., Sodroski, J., Hendrikson, W.A., 1998.
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor
and a neutralizing antibody. Nature 393, 648–659.
Marcucci, K.T., Argaw, T., Wilson, C.A., Salomon, D.R., 2009. Identiﬁcation of two dis-
tinct structural regions in a human porcine endogenous retrovirus receptor,
HuPAR, contributing to function for viral entry. Retrovirology 6 (3).
Mattiuzzo, G., Takeuchi, Y., 2010. Suboptimal porcine endogenous retrovirus infection
in non-human primate cells: implication for preclinical xenotransplantation. PLoS
One 5 (10), e13203.
Mattiuzzo, G., Matouskova, M., Takeuchi, Y., 2007. Differential resistance to cell entry by
porcine endogenous retrovirus subgroup A in rodent species. Retrovirology 4, 93.
Mazari, P.M., Linder-Basso, D., Sarangi, A., Chang, Y., Roth, M.J., 2009. Single-round se-
lection yields a unique retroviral envelope utilizing GPR172A as its host receptor.
Proc. Natl. Acad. Sci. U. S. A. 106 (14), 5848–5853.
Olah, Z., Lehel, C., Anderson, W.B., Eiden, M.V., Wilson, C.A., 1994. The cellular receptor
for gibbon ape leukemia virus is a novel high afﬁnity sodium-dependent phos-
phate transporter. J. Biol. Chem. 269 (41), 25426–25431.
Rigby, M.A., Rojko, J.L., Stewart, M.A., Kociba, G.J., Cheney, C.M., Rezanka, L.J., Mathes,
L.E., Hartke, J.R., Jarrett, O., Neil, J.C., 1992. Partial dissociation of subgroup C pheno-
type and in vivo behaviour in feline leukaemia viruses with chimeric envelope
genes. J. Gen. Virol. 73, 2839–2847.
Rohn, J., Linenberger, M., Hoover, E., Overbaugh, J., 1994. Evolution of feline leukemia
virus variant genomes with insertions, deletions, and defective envelope genes in
infected cats with tumors. J. Virol. 68 (4), 2458–2467.
Sarangi, A., Bupp, K., Roth, M.J., 2007. Identiﬁcation of a retroviral receptor used by an
Envelope protein derived by peptide library screening. Proc. Natl. Acad. Sci. U. S. A.
104 (26), 11032–11037.
Steck, F.T., Rubin, H., 1966. The mechanism of interference between an avian leukosis
virus and Rous sarcoma virus. II. Early steps of infection by RSV under conditions
of interference. Virology 29, 642–653.
Takeuchi, Y., Vile, R.G., Simpson, G., O'Hara, B., Collins, M.K.L., Weiss, R.A., 1992. Feline
leukemia virus subgroup B uses the same cell surface receptor as gibbon ape leuke-
mia virus. J. Virol. 66, 1219–1222.
Takeuchi, Y., Patience, C., Magre, S., Weiss, R.A., Banerjee, P.T., Tissier, P.L., Stoye, J.P.,
1998. Host range and interference studies of three classes of pig endogenous retro-
virus. J. Virol. 72 (12), 9986–9991.
Ting, Y.T., Wilson, Carolyn A., Farrell, Karen B., Chaudry, G. Jilani, Eiden, Maribeth V.,
1998. Simian sarcoma-associated virus fails to infect Chinese Hamster cells despite
the presence of functional gibbon ape leukemia virus receptors. J. Virol. 72 (12),
9453–9458.
Wilson, C.A., Eiden, M.V., 1991. Viral and cellular factors governing hamster cell in-
fection by murine and gibbon ape leukemia viruses. J. Virol. 65 (11),
5975–5982.
Wilson, C.A., Wong, S., VanBrocklin, M., Federspiel, M.J., 2000. Extended analysis of the
in vitro tropism of porcine endogenous retrovirus. J. Virol. 74 (1), 49–56.
Yao, Y., Yonezawa, A., Yoshimatsu, H., Masuda, S., Katsura, T., Inui, K., 2010. Identiﬁ-
cation and comparative functional characterization of a new human riboﬂavin
transporter hRFT3 expressed in the brain. J. Nutr. 140 (7), 1220–1226.
Yonezawa, A.M.S., Kasura, T., Inui, K., 2008. Identiﬁcation and functional characteriza-
tion of a novel human and rat riboﬂavin transporter, RFT1. Am. J. Physiol. Cell
Physiol. 295 (3), C632–C641.
Zhao, Y., Zhu, L., Lee, S., Li, L., Chang, E., Soong, N., Douer, D., Anderson, W., 1999.
Identiﬁcation of the block in targeted retroviral-mediated gene transfer. Proc.
Natl. Acad. Sci. U. S. A. 96 (7), 4005–4010.
